EGFR and non-small cell lung carcinoma: Dacomitinib, a second-generation irreversible EGFR inhibitor, which has been found to be successful in the treatment of non-small-cell lung cancer, reached phase II trials in patients with recurrent glioblastoma patients with EGFR amplification with or without EGFR variants.